think teva
see dramat revers sentiment teva announc restructur
plan decemb promis cost cut dramat exceed estim
compani guidanc disclosur fremanezumab could delay
given investor paus sidelin teva share base near-
term dynam gener industri on-going pressur declin
copaxon franchis howev gener price appear stabil kare
schultz promis action right-siz compani cost structur want
revisit invest thesi see whether share offer opportun
gener price seem stabil teva pipelin seem rel bare
outsiz contribut product gener nexium gener concerta
caus teva competit posit fall roughli market share pro forma
time acquisit actavi gener last year actavi wasnt intend
give teva addit share manag highlight strateg valu
actavi pipelin opportun date howev teva hasnt abl capit
pipelin seem unlik next two year vesicar forteo
key opportun next month insuffici off-set pressur
current on-market portfolio within gener prefer overweight top
pick base upcom launch key gener opportun includ gener
copaxon obvious teva expens advair restasi biosimilar neulasta
remain construct launch fremanezumab austedo think
theyr unlik suffici off-set continu declin copaxon teva
remov risk coven breach recent b/ action although compani
littl flexibl oper seem unlik hit manag target
leverag new ceo kare schultz bring much need credibl
teva manag weve impress decis someth miss
teva recent year although think face much difficult setup
turnaround lundbeck
teva quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight teva recent acquisit
actavi gener busi extend industri
leadership teva also benefit key
brand product includ
bolster franchis affect
gener competit copaxon
cautiou near-term given concern price
teva could trade mileston
achiev brand pipelin product well
unexpect product approv core gener
evid greater pressur gener price
manag unabl creat confid regard
pipelin opportun brand busi poor
integr execut actavi gener
new ceo kare schultz bring much need credibl teva compani
forc lower expect meaning wake acquisit actavi
gener busi number come carri signific debt
question compani surviv especi launch gener
version copaxon mr schultz come teva engin success turnaround
lundbeck overweight cover emili field import recogn two
situat differ
mr schultz need fix teva gener busi reason compani
promis brand asset fremanezumab austedo limit balanc sheet
build pipelin mr schultz necess engag aggress cost-cut
initi worri might result underinvest gener busi
weaken competit posit gener market come
signific pressur broader market forc bare much blame hard us
think teva challeng small part due inconsist leadership
ceo also within gener divis last six year teva fifth
divis head time
report review key issu face compani gener
busi well see compani two key brand asset fremanezumab
austedo also provid context mr schultz tenur lundbeck
turnaround differ face teva
shift gener market structur
teva gener busi impact chang structur gener
market inher benefit biggest player industri isnt great
weve seen surg fda approv begin caus establish market
leader cede share smaller player scale view signific competit
advantag although buy consortium becom sophist manag
supplier well show greater willing sourc product newer player
gdufa view win -base manufactur level play
field complianc standpoint extens cost improv assur qualiti
exu manufactur perhap increas confid sourc product
market structur averag market share per product y-axi number product x-axi bubbl
key contributor gener price eros increas competit seen within
product chart show gener compani coverag
averag number competitor per drug product group steadili increas time
number compani market number product
number product
averag number competitor per drug product time
last year gener product approv launch acceler caus
price erod much faster histor norm data show approxim
gener product launch sinc begin
product launch product clearli launch product market
alreadi competit averag number competitor new launch
grown
averag number competitor new launch time launch
also analyz new launch affect market share incumb
compani alreadi produc product teva lost nearli
bp share within product also lost signific share go
market share includ product new launch post
time nearli compani launch new product teva
launch nearli product indian manufactur clearli shape market
anda approv compar top four player
market teva novartis/sandoz
number gener product launch sinc
across coverag except much differ busi model
tradit gener manufactur data show gener
compani lost market share higher proport portfolio greater
competitor product teva seen increas product less
market share number product market share stay rel
across across entir portfolio averag market share per product
teva reduc nearli refer teva wasnt alon
myl averag market share per product go went
teva number competitor per drug product
ten comp
teva average market share within product number
product within market share rang im sale
challeng howev there reason think mani specif
teva alway motif within gener industri though year
teva primari larg consolid acquir ivax barr actavi
time player gener market
compar teva market share defin iqvia sale teva given
compar top player especi term dollar market share
compar sandoz endo given rel modest amount
even seen share defin dollar valu increas
fair good deal teva lost share relat divestitur mandat
ftc close actavi transact degre measur bad luck
certainli fault current manag team like due compani
includ provis either reduc price give teva option cancel
potenti merger becam obviou ftc condit would much greater
origin envis
teva lost share rel gener leader
chang
chang
interestingli despit actavi acquisit there evid teva portfolio
becom commodit weve often look ratio compani market
share sale measur iqvia benchmark recogn limit
compani market share lower ratio reflect greater mix commod
product even addit actavi gener busi histor carri
high dollar/script ratio teva ratio slip
teva gener portfolio lost valu
ratio
share
ratio
share
follow acquisit actavi teva held global gener medicin overview
investor laid mani futur product pipelin present
focus combin near-term long-term opportun come year
teva fell well short target million new product launch clear
miss result legal setback nuvar
other saw teva unabl win regulatori approv despit settlement clear
launch byetta exenatid compani expect launch
teva disclos product first-to-fil opportun
month stay expir product teva thu far launch seven
total sale accord im
launch disclos opportun analyst day present
miss launch disclos opportun analyst day present
teva tent approv
teva tent approv
teva lost appeal feder circuit
patent trial oct launch
expect
apotex ascend aurobindo prasco gener effient market
meet teva disclos beyond launch opportun well product
confidenti settlement case dismiss includ product
altern dosag form inject topic patch ophthalm
product three larger opportun includ gener januvia/janumet
im sale forteo im sale latuda im sale
sever sizeabl dont seem like materi time
compani best launch like vesicar ciali also goe gener year
although expect multipl entrant argentum date certain launch teva dearth
new product opportun along unfavour market dynam like explain
teva disclosur last month didnt expect gener busi
return growth
forteo repres key opportun teva although product nuanc
decemb teva settl forteo patent litig teva partner
antar pharma manufactur multi-dos pen devic state
believ teva may ftf statu entitl day market exclus
note key forteo patent set expir august lilli agre sue
teva regard devic patent antar suppli devic margin also
receiv high single-digit royalti teva sale
januari teva also abl avoid anoth setback gener forteo
applic fda deni amneal citizen petit ask agenc refrain
approv anda contain synthet deriv teriparatid approv
anda contain recombin human parathyroid hormon teva product
synthet deriv reject amneal petit fda cite octob draft
guidanc anda synthet peptid product state long synthet
peptid refer recombin rld show impur level new
impur drug substanc character new specifi
impur justifi new impur affect safeti
favor cp rule follow anoth happen januari fda
deni cp request fda deni anda use forteo rld
forteo recombin protein fulli character also
consid gener therapeut equival unless gener applic perform clinic
crossov studi deni request fda predict state
grant lilli request could effect take final action approv
specif aspect applic propos teriparatid product
opportun either fulli review data inform submit applic
fda use reason previous deni request certain standard
appli product prior review anda
although teva may entitl day period exclus gener forteo
opportun may diminish current level tymlo parathyroid hormon analogu
market moa forteo launch june
although ab-rat gener im script data show tymlo steadili take
share forteo current share radiu price tymlo
discount forteo wac basi importantli addit take share appear
slightli grow market well tymlo forteo combin
januari also plan enter market anoth analogu
forteo current clinic trial expect submit applic fda
possibl approv abl gain approv market like
erod manufactur forc compet price even isnt blockbust
could much-need high valu launch teva
sunovion treatment schizophrenia bipolar latuda present appeal court
litig februari district court judg stanley chesler rule gener filer
teva emcur state key patent valid enforc
gener manufactur prohibit commerci gener prior patent
expir januari issu claim patent depict
chemic structur singl enantiom lurasidon teva/emcur contend
depict patent repres racem mixtur chemist often draw singl
enantiom shorthand racem mixtur teva/emcur cite two text book
evid teva emcur gener candid singl enantiom lurasidon
basi case non-infring judg rule feb left
door open defend appeal claim construct markman decis
claim oral argument appeal held februari
see unlik defend win appeal district court judg succinctli
state main problem defend propos construct claim
court discern basi feder circuit law claim
construct defend articul basi read appeal
document appear teva/emcur repeat mani argument fail
cite relev case law decis expect later year said sinc key
patent expir earli win teva would grant extra month
sale note multipl gener manufactur addit teva emcur
aim enter market patent expiri includ amneal
innov
gener
teva settl launch
teva sun alemb tent
teva zydu ajanta glenmark
patent invalid
approv tent approv
accord glenmark stride
amneal su first august
amneal wockhardt tent
apotex tent approv
teva
expect
appeal progress oral
argument held feb
rule feb
emcur su first jan teva
zydu sun tent
settl
believ teva ftf
day exclus
rule actavi
gener
may delay
patent expiri sept
beyond gener launch opportun
innov
teva tent
brand gener
gener
follow teva
cipla cipla
emtricitabin
aurobindo
litig on-going
amneal
macleod
teva aurobindo
known filer
tent approv
entitl
revenu
cipla litig
possibl filer
consensu zydu tent approv multipl
alemb apotex
accord alemb
sandoz amneal
teva cipla tent
bench trial multipl
filer schedul june
jan accord
msn aurobindo
recoveri us gener busi question takeaway
file februari teva need reli specialti brand perform
off-set near-term weak brand side busi fremanezumab
compani cgrp peptid target agent austedo indic chorea associ
huntington diseas tardiv dyskinesia becom import pillar busi
despit face competit
fact recent pipelin setback wed argu within specialti brand portfolio
austedo fremanezumab fact teva real shot goal arguabl
compani best chanc off-set lost earn copaxon franchis alreadi
face two competitor wouldnt surpris third entrant market
within next month
teva collabor activ biotech laquinimod view heir
appar teva multipl sclerosi copaxon franchis fail may miss
phase endpoint failur primari endpoint came teva halt higher
dosag arm trial incid cardiovascular side effect
bronchospasm exercis induc
first-lin treatment
disclosur teva indic januari warn letter remedi pathway may result approv delay
